D
David A. DeMicco
Researcher at Pfizer
Publications - 84
Citations - 7464
David A. DeMicco is an academic researcher from Pfizer. The author has contributed to research in topics: Atorvastatin & Statin. The author has an hindex of 35, co-authored 83 publications receiving 6540 citations. Previous affiliations of David A. DeMicco include New York University.
Papers
More filters
Journal ArticleDOI
Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy A Meta-analysis
David Preiss,Sreenivasa Rao Kondapally Seshasai,Paul Welsh,Sabina A. Murphy,Jennifer E. Ho,David D. Waters,David A. DeMicco,Philip J. Barter,Christopher P. Cannon,Marc S. Sabatine,Eugene Braunwald,John J.P. Kastelein,James A. de Lemos,Michael A. Blazing,Terje R. Pedersen,Matti J. Tikkanen,Naveed Sattar,Kausik K. Ray +17 more
TL;DR: In this paper, the authors investigated whether intensive-dose statin therapy is associated with increased risk of new-onset diabetes compared with moderate-dose stochastic insulin this paper.
Journal ArticleDOI
Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins: A Meta-analysis
S. Matthijs Boekholdt,Benoit J. Arsenault,Samia Mora,Terje R. Pedersen,John C. LaRosa,Paul J. Nestel,R. John Simes,Paul N. Durrington,Graham A. Hitman,K. M. A. Welch,David A. DeMicco,Aeilko H. Zwinderman,Michael Clearfield,John R. Downs,Andrew Tonkin,Helen M. Colhoun,Antonio M. Gotto,Paul M. Ridker,John J.P. Kastelein +18 more
TL;DR: Among statin-treated patients, on-treatment levels of LDL-C, non-HDL-C and apoB were each associated with risk of future major cardiovascular events, but the strength of this association was greater for non- HDL-C than for LDL-B and apolipoproteins.
Journal ArticleDOI
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: A meta-analysis of statin trials
S. Matthijs Boekholdt,G. Kees Hovingh,Samia Mora,Benoit J. Arsenault,Pierre Amarenco,Terje R. Pedersen,John C. LaRosa,David D. Waters,David A. DeMicco,R. John Simes,Antony C. Keech,David Colquhoun,Graham A. Hitman,D. John Betteridge,Michael Clearfield,John R. Downs,Helen M. Colhoun,Antonio M. Gotto,Paul M. Ridker,Scott M. Grundy,John J.P. Kastelein +20 more
TL;DR: Patients who achieve very low LDL-C levels have a lower risk for major cardiovascular events than do those achieving moderately low levels and the association between very low levels of atherogenic lipoproteins achieved with statin therapy and cardiovascular disease risk is well-documented.
Journal ArticleDOI
Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment
John J.P. Kastelein,Wim A. van der Steeg,Ingar Holme,Michael Gaffney,Nilo B. Cater,Philip J. Barter,Prakash Deedwania,Anders G. Olsson,S. Matthijs Boekholdt,David A. DeMicco,Michael Szarek,John C. LaRosa,Terje R. Pedersen,Scott M. Grundy +13 more
TL;DR: In patients receiving statin therapy, on-treatment levels of non-HDL cholesterol and apolipoprotein B were more closely associated with cardiovascular outcome than levels of LDL cholesterol.
Journal ArticleDOI
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease LEADe
Howard Feldman,Rachelle S. Doody,Miia Kivipelto,D L Sparks,David D. Waters,Roy W. Jones,Elias Schwam,Rachel Schindler,Judith Hey-Hadavi,David A. DeMicco,Andrei Breazna +10 more
TL;DR: This study provides Class II evidence that intensive lipid lowering with atorvastatin 80 mg/day in patients with mild to moderate probable Alzheimer disease, taking donepezil, with low-density lipoprotein cholesterol levels between 95 and 195 mg/dL over 72 weeks does not benefit cognition.